The Centre for Oncology Education and Research Translation (CONCERT) was established at 1st July 2014 as part of the Cancer Institute NSW (CINSW) initiative for Translational Cancer Research Centres (TCRC). CONCERT’s large demographic footprint serves more than 5,500 new cancer patients in NSW each year, equivalent to 16% of cancer incidence in NSW; including potentially more vulnerable populations of culturally and linguistically diverse backgrounds or living in rural/remote areas.

CONCERT brings together a diverse consortium of more than 300 professional members spanning all aspects of cancer research, diagnosis, treatment and care, with a growing membership over the last years – 2016 Member numbers in South West Sydney and Illawarra Shoalhaven Local Health Districts and in the ACT; and breakdown of membership research profession.  

 Our institutional parties include:

  • Universities: 

University of New South Wales

Western Sydney University

University of Wollongong

Australian National University

University of Canberra

  • Medical Research Institutes

Ingham Institute for Applied Medical Research

Illawarra Health and Medical Research Institute

  • South Western Sydney Local Health District and Hospitals

Liverpool Hospital

Campbelltown Hospital

Bankstown-Lidcombe Hospital

Braeside Hospital

Camden Hospital

Bowral Hospital

  • Illawarra Shoalhaven Local Health District and Hospitals

Wollongong Hospital

Nowra Hospital

Milton Hospital

Bathurst Hospital

Orange Hospital

  • Health Directorate ACT Government and Hospitals

Canberra Hospital



CONCERT’s two flagships, Targets & Therapeutics (T1/T2) and Practice and Policy (T2/T3), span translational research across the Bench-Bedside-Policy continuum. Our translational research programs aim to improve the lives of cancer patients and their carers throughout their journey from diagnosis, treatment and right through to survivorship.



CONCERT’s flagship programs aim to:

  • develop new treatment technologies to better target cancers and improve cure rates and reduce undesired side effects for patients with colorectal, head & neck and brain cancers
  • accelerate the discovery program for tumour biomarkers for the greater understanding of the complex relationship between the biology of tumours and psychosocial behaviour (e.g. anxiety) of patients
  • develop electronic systems to capture information about patients’ physical and psychological wellbeing to systematically inform their self-management, clinical and psychosocial care
  • study the presence of Circulating Tumour Cells (CTC) in the blood of patients to assess the prognostic significance of CTC and examine whether this technique improves timely monitoring of therapy response.

CONCERT’s key facilities, technology platforms and expertise include cancer tissue biobanking, circulating tumour cell analyses, advanced imaging facilities like MRI-Linac, clinical registry and cancer services, clinical trial capacity and expertise in psycho-oncology, supportive and palliative care. An important aim of CONCERT is capacity building through education and training of the upcoming generation of researchers, clinicians and cancer-focused healthcare professionals, with access to PhD programs and mentoring by experienced cancer research and care professionals.